RZLT

Rezolute, Inc.

Healthcare
Biotechnology
$406M market cap

Forecast run · Sep 14, 2026Upside rank 594 of 3,136

Model Signal

ForecastQ Daily Probabilities

53.5%

37.6%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$4.22

Price target$8.67

Implied move+105.5%

Analysts12

ForecastQ Portfolios

RZLT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.